Differential role of CCR2 in the dynamics of microglia and perivascular macrophages during prion disease by Gomez-Nicola, Diego et al.
RESEARCH ARTICLE
Differential Role of CCR2 in the Dynamics of
Microglia and Perivascular Macrophages
During Prion Disease
Diego Gomez-Nicola, Sjoerd T.T. Schetters, and V. Hugh Perry
The expansion of the microglial population is one of the hallmarks of numerous brain disorders. The addition of circulating
progenitors to the pool of brain macrophages can contribute to the progression of brain disease and needs to be precisely
defined to better understand the evolution of the glial and inflammatory reactions in the brain. We have analyzed the degree
of infiltration/recruitment of circulating monocytes to the microglial pool, in a prion disease model of chronic neurodegenera-
tion. Our results indicate a minimal/absent level of CCR2-dependent recruitment of circulating monocytes, local proliferation
of microglia is the main driving force maintaining the amplification of the population. A deficiency in CCR2, and thus the
absence of recruitment of circulating monocytes, does not impact microglial dynamics, the inflammatory profile or the tempo-
ral behavioral course of prion disease. However, the lack of CCR2 has unexpected effects including the failure to recruit peri-
vascular macrophages in diseased but not healthy CNS and a small reduction in microglia proliferation. These data define the
composition of the CNS-resident macrophage populations in prion disease and will help to understand the dynamics of the
CNS innate immune response during chronic neurodegeneration.
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Introduction
The determination of the relative contribution of local pro-liferation of microglial cells vs. the infiltration of bone-
marrow derived progenitors during CNS pathology is a mat-
ter of intense debate. The recruitment of circulating progeni-
tors or monocytes has been evidenced in models of
neurodegeneration (Prinz and Mildner, 2011) highlighting
the different roles of these cells and resident microglia in, for
example, regulating amyloid [(Ab) clearance in model of Alz-
heimer’s disease (AD)] (Simard et al., 2006). However, the
current trend supports in situ microglial proliferation as the
major mechanism regulating microglial turnover, with little or
no contribution of circulating progenitors (Gomez-Nicola
et al., 2013; Lawson et al., 1992; Mildner et al., 2011). Cir-
culating Ly6ChiCCR21 monocytes are able to infiltrate the
brain and influence pathology under certain conditions (brain
preconditioning; Mildner et al., 2007, 2011). CCR22/2 mice
have a greatly decreased Ly6ChiCCR21 monocyte population
and recruitment to the CNS parenchyma is CCR2-dependent
making them a valuable model in which to study the role of
recruited monocytes in chronic neurodegeneration (Mildner
et al., 2007). Previous studies using CCR22/2 mice reported
decreased survival and increased Ab load in APP or APP/PS1
transgenic mice and, to some extent, a reduction of the
microglial numbers in the brain (El Khoury et al., 2007;
Naert and Rivest, 2011). More recently, the increase in Ab
deposition was correlated with a defect in perivascular macro-
phages, rather than an impact over the microglial population
(Mildner et al., 2011). However, it is unclear how the popu-
lation of CNS-resident macrophages may be modulated in
the context of other models of neurodegeneration, such as
prion disease, where a massive expansion of the microglial
population accounts for a significant pathological component
of the disease (Gomez-Nicola et al., 2013).
Experimental models of prion disease are tractable labo-
ratory models in which to study protein misfolding,
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progressive neuronal degeneration, synaptopathy, and the
characteristic glial inflammatory response common to several
neurodegenerative diseases (Ransohoff and Perry, 2009). In
prion disease, a 10-fold expansion of the microglial popula-
tion is observed, associated with the local proliferation of resi-
dent microglia driven through the CSF1R pathway (Gomez-
Nicola et al., 2013). Abrogating microglial proliferation by
selective targeting of the CSF1R activation has a protective
effect and delays the progression of the clinical symptoms of
the disease (Gomez-Nicola et al., 2013). Although CCR2
deficiency has been shown not to affect the survival of prion
diseased mice (Tamguney et al., 2008), some studies suggest a
contribution from bone-marrow derived cells to the micro-
glial population (Priller et al., 2006) although this latter study
was confounded by the effects of brain irradiation. Therefore,
the degree of infiltration of circulating progenitors, even if
small, needs to be evaluated in order to better understand the
composition of the macrophage populations of the brain in
progressive neurodegeneration.
We have studied the potential contribution of circulat-
ing monocytes or progenitors to the pool of macrophages/
microglia in prion disease, using tracing techniques and inves-
tigated the role of CCR2 in the cell populations’ dynamics.
We provide evidence for a minimal/absent recruitment of cir-
culating progenitors to the brain parenchyma, and report on
the effects of CCR2 over the control of microglial and peri-
vascular macrophage proliferation during the neurodegenera-
tive process.
Materials and Methods
Experimental Model of Prion Disease
Female C57BL/6J (Harlan, Bicester, UK), c-fms-EGFP (Sasmono
et al., 2003; macgreen), and C57BL/6J-CCR22/2 mice (Menzies
et al., 2012) were bred and maintained in local facilities. Mice
expressing EGFP under the promoter of c-fms (CSF1R) are charac-
terized by the expression of green fluorescence in microglial cells.
Mice were housed in groups of 4–10, under a 12-h light/12-h dark
cycle at 21C, with food and water ad libitum. Prion disease was
induced under anesthesia with a ketamine/rompun mixture (85 and
13 mg/kg, respectively), and injection of 1 lL of either ME7-
derived (ME7-animals; 10% w/v) or normal brain homogenate
(NBH-animals), injected stereotaxically and bilaterally in the brain
at the coordinates from bregma: anteroposterior, 22.0 mm; lateral,
21.7 mm; depth, 1.6 mm. When required, mice were given an
intraperitoneal (i.p.) injection of BrdU (Sigma-Aldrich; 7.5 mg/mL,
0.1 mL/10 g weight in sterile saline), on the 2 days before the end
of the experiment. All procedures were performed in accordance
with UK Home Office licensing.
Tracing of Circulating Cells with CFDA
A stock solution of CFDA (VybrantVR CFDA SE Cell Tracer Kit,
Molecular Probes) was prepared by dissolving 0.5 mg CFDA in 90
lL of dimethyl sulfoxide. A labeling solution (2% CFDA in sterile
saline) was then prepared and after thorough mixing, injected (10
mL/g body weight) over a 5-min period via the tail vein of restrained
conscious NBH (control) and ME7 (prion) mice, at 12 weeks post-
induction. Similar results were obtained by injecting 100 mL intra-
splenically after abdominal surgery, as previously reported (Bech-
mann et al., 2005). The animals were sacrificed at 48 h after the
injection, to examine cell migration to the brain parenchyma.
Behavioral Tests
CCR2-deficient (CCR22/2) or wild-type (WT) mice treated with
NBH or ME7 (n5 6/group), were tested weekly on behavioral tasks
from the 13th week post-injection, previously demonstrated to detect
the onset of behavioral dysfunction (Guenther et al., 2001): open-
field locomotor activity, burrowing activity, and motor performance
on an inverted screen were assessed.
Open-Field Locomotor Activity
The open-field tests were carried out using activity monitoring soft-
ware (Med Associated). The mice were placed in individual cages of
27 3 27 3 0.3 cm for a period of 3 min, to further analyze the
total distance travelled (cm) and the number of ambulatory counts,
using the average speed as an internal control of the mouse motor
abilities, during the test period (3 min).
Burrowing
Plastic cylinders, 20 cm long and 6.8 cm in diameter were filled
with 190 g of normal diet food pellets and placed in individual
mouse cages. Mice were placed individually in the cages overnight,
weighting the remaining pellets at the end of the session, and calcu-
lating the amount displaced (“burrowed”). The mice were then
returned to their home cage.
Inverted Screen
The inverted screen is a 43-cm2 of wire mesh consisting of 12 mm2
of 1 mm diameter wire, surrounded by a 4-cm wooden bead to pre-
vent the mouse from escaping the screen. Each mouse was placed in
the center of the square and the screen inverted over 2 s, with the
head of the mouse declining first. The screen was held steadily 20–
30 cm above a padded surface. The time at which the mouse fell off
was noted, or the mouse was removed when reaching the maximum
time of the assay (120 s; Guenther et al., 2001).
Body Weight and Late-Stage Clinical Signs of
Disease
Body weights of all mice were monitored on a weekly basis from 8
weeks post-injection. Terminal disease was defined as a humane end-
point of a loss of 15% body weight and/or the development of
severe clinical signs; at this point animals were sacrificed.
Immunohistochemistry
Coronal hippocampal sections were cut from paraformaldehyde-
fixed, frozen, or fresh brains. Mice perfusion, tissue processing and
immunohistochemical analysis was performed as previously described
(Gomez-Nicola et al., 2008, 2013), using the following primary
antibodies: goat anti-Iba1 (Wako), rat anti-CD11b (ABD Serotec),
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chicken anti-GFP (Abcam), mouse anti-GFAP (Millipore), rat anti-
CD34 (Abcam), rat anti-CD34 (BD Biosciences), rat anti-Ly6c
(ABD Serotec), rabbit anti-laminin (Sigma-Aldrich), mouse anti-
BrdU (DSHB), rat anti-BrdU (Santa Cruz Biotechnologies), rabbit
anti-PU.1 (Cell Signaling), rabbit anti-CCR2 (Abcam), rat anti-
CD206 (Mannose receptor, AbD Serotec), and rat anti-MHCII
(EBioscience). Following primary antibody incubation, the sections
were washed and incubated with the appropriate biotinylated sec-
ondary antibody (Vector Labs), and/or with the appropriate Alexa
405, 488, or 568 conjugated secondary antibody or streptavidin
(Molecular Probes). For light microscopy, the sections were visual-
ized using diaminobenzidine (DAB) precipitation, in a Leica CTR
5000 microscope, coupled to a Leica DFC300FX microscope cam-
era. When required, the DAB signal was enhanced with 0.05%
nickel ammonium sulfate, producing a black precipitate. After
immunofluorescence labeling, nuclei were visualized by DAPI stain-
ing and the sections were mounted with Mowiol/DABCO (Sigma-
Aldrich) mixture. The sections were visualized on a Leica TCS-SP5
confocal system, coupled to a Leica CTR6500 microscope.
The general immunohistochemistry protocol was modified for
the detection of BrdU, adding a DNA denaturation step with 2N
HCl (30 min, 37C), as previously described (Gomez-Nicola et al.,
2011, 2013).
Quantification and Image Analysis
The quantification of antigen positive cells (i.e., Iba11) or antigen
positive area (i.e., GFAP) was performed after DAB immunohisto-
chemistry (n5 4 fields/mouse, n5 4–6 mice/group), as previously
described (Gomez-Nicola et al., 2010, 2013). Data were represented
as number of positive cells/mm2. All quantifications were performed
with the help of the ImageJ image analysis software.
Analysis of Gene Expression by RT-PCR
CCR2-deficient (CCR22/2) or WT mice treated with NBH or
ME7 (n5 4–6/group) were processed to obtain samples from the
hippocampus or the thalamus by dissection under a microscope,
after intracardiac perfusion with heparinized 0.9% saline. RNA was
extracted using the RNAqueousVR -Micro Kit (Life Technologies),
quantified using Nanodrop (Thermo Scientific), to be retrotran-
scribed using the iScript cDNA Synthesis Kit (Bio-Rad), following
manufacturer’s instructions, after checking its integrity by electropho-
resis in a 2% agarose gel. cDNA libraries were analyzed by qPCR
using the iTaq Universal SYBR Green supermix (Bio-Rad) and the
following custom designed gene-specific primers (Sigma-Aldrich):
csf1 (NM_007778.4; FW, agtattgccaaggaggtgtcag, RV, atctggcatga
agtctccattt), il34 (NM_001135100.1; FW, ctttgggaaacgagaatttggaga,
RV, gcaatcctgtagttgatggggaag), csf1r (NM_001037859.2; FW, gcag
taccaccatccacttgta, RV, gtgagacactgtccttcagtgc), pu.1 (NM_011355.1;
FW, cagaagggcaaccgcaagaa, RV, gccgctgaactggtaggtga), c/ebpa
(NM_007678.3; FW, agcttacaacaggccaggtttc, RV, cggctggcgacatacag
tac), runx1 (NM_001111021; FW, caggcaggacgaatcacact, RV, ctcgtg
ctggcatctctcat), irf8 (NM_008320; FW, cggggctgatctgggaaaat, RV,
cacagcgtaacctcgtcttc), cd34 (NM_133654.3; FW, gccctacaggagaaaggct
gggt, RV, gcccctcgggtcacattggc), c-kit (NM_021099.3; FW, cgtcttccg
gcacaacggca, RV, tgagcagcggcgtgaacagag), sca1 (NM_009124.6; FW,
cccggggtggccgtgatac, RV, agctggctggtccgctcagg), ccl2 (NM_011333.3;
FW, ttaaaaacctggatcggaaccaa, RV, gcattagcttcagatttacgggt), ccr2
(NM_009915; FW, aggagccatacctgtaaatgcc, RV, tgtggtgaatccaatgccct),
il1b (NM_008361.3; FW, gaaatgccaccttttgacagtg, RV, tggatgctctcatca
ggacag), tgfb (NM_011577; FW, tgtacggcagtggctgaacc, RV, cgtttgg
ggctgatcccgtt), mhc class II antigen A, alpha (H2-Aa) (mhcII;
NM_010378.2; FW, agctctgattctgggggtcctcg, RV, ataaacgccgtctgtgact
gact), and ym1 (NM_009892; FW, atggaagtttggacctgccc, RV, agtagc
agccttggaatgtctt). Quality of the primers and the PCR reaction were
evaluated by electrophoresis in a 1.5% agarose gel, checking the
PCR product size. Data were analyzed using the 2-DDCt method
with Primer Opticon 3 software, using gapdh (NM_008084.2; FW,
tgaacgggaagctcactgg, RV, tccaccaccctgttgctgta) as a housekeeping
gene.
Statistical Analysis
All experiments were designed and performed in accordance with the
ARRIVE guidelines. Data were expressed as mean6 SEM and ana-
lyzed with the GraphPad Prism 5 software package (GraphPad Soft-
ware). For all data sets, normality and homoscedasticity assumptions
were reached, validating the application of the one-way or two-way
ANOVA, followed by the Tukey post hoc test for multiple
comparisons.
Results
Prion disease causes a mild expansion of the
CD341 population while driving no detectable
recruitment of circulating progenitors to the brain
parenchyma
Following our recent findings defining the control and conse-
quences of microglial proliferation in prion disease (Gomez-
Nicola et al., 2013), we now set out to characterize the
potential contribution of infiltrated peripheral precursor cells
to the disease. We analyzed the expression or localization of
different markers of peripheral precursor cells or hematopoi-
etic stem cells during the time course of prion disease (Fig.
1). First, we analyzed the expression of CD341 during prion
disease (Fig. 1A), an antigen reported as characteristic of pro-
liferating microglial cells (Ladeby et al., 2005b). CD341 cells
show a trend to be more numerous in prion disease mice
when compared with the NBH group, more evident in the
thalamus at late-stage disease (Fig. 1A). A similar trend was
observed in the other areas analyzed (data not shown), as well
as at the mRNA level (Fig. 1B). The analysis of the mRNA
expression of c-kit and sca1, markers for bone-marrow pro-
genitors, showed no significant increase in prion diseased
brain, when compared with the NBH controls (Fig. 1B).
Next, we analyzed the identity of Ly6c-expressing cells,
an antigen characteristic of endothelial cells and infiltrated
monocytes (Mildner et al., 2007; Prinz and Mildner, 2011).
The expression of Ly6c (Fig. 1C; red) in prion diseased brains
is absent from microglial cells (Fig. 1C; GFP1), as evidenced
by confocal microscopy. Ly6c (Fig. 1D; red) is expressed in
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FIGURE 1: Analysis of the infiltration of peripheral monocyte precursors in prion diseased brain. (a) Immunohistochemical analysis of the
expression of CD34 in the CA1 region of the hippocampus and the thalamus of prion disease (ME7) and control (NBH) mice. Quantified data
expressed as mean6SEM of the number of CD341 cells/mm2. (b) Analysis of the expression of mRNA of CD34, c-kit and SCA1 in the hippo-
campus (CA1) and thalamus of prion disease (ME7) and control (NBH) mice. Expression of CD34, c-kit and SCA1 represented as mean6SEM
and indicated as relative expression levels using the 22DDCt method. (c) Analysis of the infiltration of Ly6c1monocytes by double immuno-
fluorescence for Ly6c (red) and GFP (microglia, green) in the CA1 region of the hippocampus of prion disease (ME7). (d) Analysis of the
expression of Ly6c in blood vessels by triple immunofluorescence for Ly6c (red), GFP (microglia, green), and laminin (blue) in the hippocam-
pus (CA1) of prion disease mice (ME7). (e) Analysis of the infiltration of peripheral cells (CFDA1, green) in the CA1 hippocampal layer (left)
or the meningeal space (mid and right panels) in prion disease (microglia shown as CD11b1, red). White arrowheads indicate CFDA1/
CD11b1 cells. Statistical differences: *P<0.05, ** P<0.01. Data were analyzed with a two-way ANOVA and a post hoc Tukey test. (c) Nuclei
are stained with Hoechst (blue). (c, d) Fluorescent sections evaluated with confocal microscopy. Scale bar in (c, d) 50 mm; in (e) 20 mm.
blood vessels, as evidenced by its colocalisation with laminin1
capillaries (Fig. 1D; blue) but not with GFP1 microglial cells
(green). Using an alternative approach, labeling peripheral
monocytes with the fluorescent tracer CFDA, we did not
observe CD11b1 microglial cells (red) being generated from
circulating precursors (CFDA1, green) in the parenchyma of
the brain (Fig. 1E). CFDA1 cells expressing CD11b were
found in the meninges (Fig. 1E, mid and right panels; white
arrowheads) and in the perivascular space, at a similar fre-
quency in both NBH and ME7 mice.
Our results show some expansion of the CD341 cell
population, independent of the recruitment of circulating
progenitors to the microglial pool, supporting previous stud-
ies highlighting the important role of proliferation of resident
microglial cells in prion disease (Gomez-Nicola et al., 2013).
The expansion of the microglial population in prion
disease is independent of the contribution of
circulating monocytes
Given the recent evidence that the Ly-6ChiCCR21 popula-
tion of circulating monocytes infiltrates the brain during
pathology in a CCR2-dependent manner (Prinz and Mildner,
2011), we analyzed the progression of prion disease in
CCR22/2 mice. The microglial population (Iba-11 cells)
expanded to similar levels in the hippocampus (HC) of WT
and CCR22/2 mice, in response to prion disease (ME7),
when compared with NBH controls (Fig. 2A,D). The tran-
scription factor underlying microglial proliferation in prion
disease, PU.1 (Gomez-Nicola et al., 2013), is similarly
expressed in both WT and CCR22/2 mice, and is upregu-
lated in response to prion disease (Fig. 2B,D). Cell prolifera-
tion (BrdU1 cells) increases upon injection of ME7, but the
proliferative fraction of the expanding microglia population
(Brdu1/Iba-11 cells) shows a 2.64-fold increase in WT ME7-
animals, while CCR22/2 ME7-animals show a significantly
smaller 1.11-fold increase (Fig. 2C,D). The analysis of
mRNA expression by qPCR correlated with the results
obtained by immunohistochemistry (Fig. 2E). The mRNA
expression of PU.1 and C/EBPa, transcription factors regulat-
ing microglial proliferation, increases to similar levels in the
HC of both WT and CCR22/2 mice with prion disease
(ME7, 20wpi), although C/EBPa mRNA expression was
found to be relatively less expressed in CCR22/2 ME7-
animals, when compared with the WT ME7-animals (Fig.
2E) consistent with the smaller increase in Brdu labeled cells
in the CCR22/2 ME7-animals. The transcription factors
RUNX1 and IRF8, involved in the proliferation and lineage
commitment of microglia (Ginhoux et al., 2010; Kierdorf
et al., 2013), were found to be upregulated in animals with
prion disease, with no differential effect of the CCR22/2
FIGURE 1: Continued.
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FIGURE 2: Characterization of the impact of CCR2 deficiency on the dynamics and regulation of microglial proliferation in prion disease.
(a–c) Immunohistochemical analysis of the expression of Iba1 (a), PU.1 (b) and the incorporation of BrdU (c) in the CA1 region of the hip-
pocampus of prion disease (ME7) and control (NBH) mice, at 20 weeks postinduction. (d) Quantification of the number of microglial cells
(Iba11, PU.11) or proliferating cells (BrDU1); data expressed as mean6SEM of the number of antigen1 cells/mm2. (e) Analysis of the
expression of mRNA by qPCR of CSF1, IL34, CSF1R, PU.1, C/EBPa, RUNX1, and IRF8 in the hippocampus of prion disease (ME7) and
control (NBH) mice, at 20 weeks postinduction. Expression of mRNA represented as mean6SD and indicated as relative expression lev-
els to GAPDH using the 22DDCt method. Statistical differences: *P<0.05, ***P<0.001, and ****P<0.0001. Data were analyzed with a
two-way ANOVA and a post hoc Tukey test. (a, b) Nuclei are stained with Neutral Red. Scale bar in (a–c) 50 mm (in c). [Color figure can
be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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background (Fig. 2E). The expression of CSF1 and its recep-
tor CSF1R show similar patterns, appearing upregulated in
prion disease, with the CCR22/2 background having a less
pronounced effect (Fig. 2E). The expression of IL34, an alter-
native ligand for CSF1R, shows no significant change with
the different genetic backgrounds (WT vs. CCR22/2) or
experimental groups (NBH vs. ME7) used at the 20W time-
point, in accord with previously reported results (Gomez-Nic-
ola et al., 2013).
These results support the notion that the expansion of
the microglial population in prion disease is independent of
the recruitment of circulating monocytes, and is largely if not
exclusively due to proliferation of resident microglial cells.
We observed, however, that lack of CCR2 had a small but
significant effect on the microglia proliferative response.
CCR2 Deficiency Inhibits the Expansion of the
Population of Perivascular Macrophages in Prion
Disease
Following recent reports highlighting the role of perivascular
macrophages during chronic neurodegeneration (Mildner
et al., 2011), we analyzed this population in the prion dis-
eased animals (Fig. 3). Prion disease causes an expansion of
the perivascular macrophage population [Mannose receptor
(MR)1; Fig. 3A,B], when compared with NBH mice.
Although CCR2 deficiency does not impact the renewal of
the perivascular macrophage population in na€ıve or control
conditions, it inhibits the expansion of the population as
observed in comparing the WT and CCR22/2 ME7-animals
(Fig. 3A,B). We did not find a significant proliferative frac-
tion of perivascular macrophages in response to prion disease
(data not shown), validating the hypothesis that this popula-
tion is renewed/expanded from circulating progenitors
(Mildner et al., 2011). To better understand the differential
responses of the microglial and perivascular macrophages
populations (Figs. 2 and 3) we investigated the expression
of CCR2 in brains of WT ME7-animals (Fig. 3C). Confo-
cal microscopy analysis shows CCR2 expression (red) in
perivascular macrophages (MR1, blue), but not in parenchy-
mal microglial cells (GFP1) in WT ME7-animals (Fig. 3C)
and was absent in CCR22/2 mice (data not shown).
These results support a CCR2 dependent expansion of
the perivascular macrophage population in prion disease, but
not in the healthy brain.
CCR2 Deficiency Does Not Modify the Microglial
Inflammatory Response to Prion Disease
We next aimed to address the impact of CCR2 deficiency on
the generation of the microglial inflammatory response in
prion disease (Fig. 4). We first analyzed the expression of
MHCII by immunohistochemistry, and found increased
expression in ME7-animals both with a WT or CCR22/2
background (Fig. 4A,C), in accord with the results obtained
at the mRNA level (Fig. 4D). Quantitative PCR analysis of
inflammatory mediators shows a significant increase of the
expression of the proinflammatory cytokine IL1b in ME7-
animals when compared to NBH-animals (Fig. 4D), regard-
less of the genetic background (WT vs. CCR22/2). Similar
FIGURE 3: Characterization of the impact of CCR2 deficiency on the perivascular macrophage population. (a) Immunohistochemical anal-
ysis of the expression of Mannose receptor (MR; CD206) in the CA1 region of the hippocampus of prion disease (ME7) and control
(NBH) mice, at 20 weeks postinduction. (b) Quantification of the number of MR1 cells; data expressed as mean6SEM of the number of
antigen1 cells/mm2. (c) Confocal analysis of the expression of CCR2 (red) by triple immunofluorescence for MR (blue) and GFP (microglia,
green) in the hippocampus [CA1 of prion disease mice (ME7)]. Statistical differences: ** P<0.01. Data were analyzed with a two-way
ANOVA and a post hoc Tukey test. Scale bar in (a) 50 mm; in (c) 10 mm.
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results were obtained for the expression of the anti-
inflammatory cytokine TGFb, found to be upregulated in
response to prion disease, independent of the deficiency of
CCR2 (Fig. 4D). The expression of the marker of M2-like
inflammatory activation, YM1, was in accord with previously
reported data (Gomez-Nicola et al., 2013), showing non-
significant change with prion disease, and these results were
not differentially affected by the WT or CCR22/2 back-
ground (Fig. 4D). Both the chemokine CCL2 and its recep-
tor CCR2 were found to be upregulated in WT ME7-
animals (Fig. 4D), while CCR2 deficiency did not significant
alter the expression of CCL2.
Given the results regarding microglial activation in
response to prion disease upon CCR2 deficiency, we wanted
to analyze its impact on the astroglial response. Using immu-
nohistochemical analysis, we found an increased expression of
GFAP in ME7-animals, with no observed differences when
comparing WT vs. CCR22/2 mice (Fig. 4B,C).
CCR2 Deficiency Does Not Modify the Pathological
Course of Prion Disease
Following the observations that circulating progenitors do
not contribute to the microglial pool (Figs. 1 and 2) and
that CCR2 deficiency does not modify the inflammatory
FIGURE 4: Characterization of the impact of CCR2 deficiency on the inflammatory and gliotic response in prion disease. (a, b) Immunohisto-
chemical analysis of the expression of MHCII (a) and GFAP (b) in the CA1 region of the hippocampus of prion disease (ME7) and control
(NBH) mice, at 20 weeks post-induction. (c) Quantification of the number of MHCII1 or GFAP1 cells; data expressed as mean6SEM of the
number of antigen1 cells/mm2. (d) Analysis of the expression of mRNA by qPCR of MHCII, IL1b, TGFb, YM1, CCL2, and CCR2 in the hippo-
campus of prion disease (ME7) and control (NBH) mice, at 20 weeks postinduction. Expression of mRNA represented as mean6SD and indi-
cated as relative expression levels to GAPDH using the 22DDCt method. Statistical differences: * P<0.05, ** P<0.01, *** P<0.001, and
**** P<0.0001. Data were analyzed with a two-way ANOVA and a post hoc Tukey test. Scale bar in (a, b) 50 mm in (a). [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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reaction in prion disease except in the perivascular compart-
ment (Fig. 4), we examined the pathological course of the
ME7 model in WT vs. CCR22/2 mice using behavioral
techniques (Fig. 5), to address the overall contribution of
CCR2 to the disease. CCR2 deficiency did not affect the
normal decay in burrowing activity observed from the 14th
week in WT ME7-animals, maintaining a similar behavioral
trend (Fig. 5A). Similarly, we did not observe any genotype-
dependent difference in the effect of prion disease on the
loss of motor strength and motor coordination evidenced by
the inverted screen task, when compared with NBH controls
(Fig. 5B). The behavioral course of prion disease is also
characterized by a phase of hyperactivity, observed at similar
levels in WT or CCR22/2 ME7-animals and identified by
an increase in the distance travelled and the ambulatory
counts in the open field task (Fig. 5C,D). We did not
observe any difference in the behavior of control mice
(NBH) from a WT or CCR22/2 background in the
reported tests.
These results indicate that CCR2 deficiency does not
impact the pathological course of prion disease, thus support-
ing the hypothesis that there is little or no contribution of
FIGURE 5: Effect of CCR2 deficiency over the behavioral progression of prion disease. Time-course of the behavioral responses
observed in control (NBH) or prion diseased mice (ME7), with a WT or CCR22/2 genetic background. (a) Effect of the different experi-
mental groups on the burrowing behavior, measured as weight displaced (g) off the tube in 24 h. (b) Effect of the different experimental
groups on the motor performance and coordination, measured as time spent (seconds) on the inverted screen test. (c, d) Effect of the
different experimental groups on the locomotor activity, measured as distance travelled (cm) and ambulatory counts in the open field
test. Statistical differences: WT NBH vs. WT ME7 *P<0.05, ** P<0.01, *** P<0.001; CCR22/2 NBH vs. CCR22/2 ME7 # P<0.05, ##
P<0.01, ### P<0.001. Data were analyzed with a two-way ANOVA and a post hoc Tukey test.
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circulating progenitors to the microglial pool and indicating a
minimal role of the CCL2-CCR2 system on this disease.
Discussion
The expansion of the microglial population is a characteristic
of the progression of most brain pathologies. We provide evi-
dence for a minimal/absent recruitment of circulating progeni-
tors or monocytes during prion disease: recruited monocytes
make a negligible, if any, contribution to the expansion of the
microglial population, the inflammatory reaction and the
behavioral progression of the neuropathology. We recently
showed that the proliferation of microglial cells during prion
disease is controlled by the activity of the CSF1R pathway, and
blocking this receptor has a beneficial effect by delaying the
progression of the pathology (Gomez-Nicola et al., 2013). Our
results support the hypothesis of local proliferation being
responsible for the expansion of the microglial population
(Ajami et al., 2007; Mildner et al., 2007, 2011), contradicting
the earlier observed recruitment of peripheral bone-marrow
progenitors (Priller et al., 2006; Williams et al., 1995). The
recruitment of circulating progenitors to sites of evolving
chronic neurodegeneration is rare, and only seen where an
experimental alteration of the system, for example where irradi-
ation, compounds the cell migration (Mildner et al., 2011;
Prinz and Mildner, 2011). Our results may indicate the exis-
tence of a minor CD341 microglial population during neuro-
degeneration, previously identified in models of acute neural
injury (Ladeby et al., 2005a). Expression of the stem cell anti-
gen CD34 has been linked to a marked ability of self-renewal
and as a characteristic of proliferating resident microglia, and
not necessarily of infiltrating bone-marrow precursors (Ladeby
et al., 2005b). However, further experiments would be neces-
sary to support the existence of a highly proliferative CD341
microglial subpopulation in prion disease.
The evidence reported here shows that there is minimal
impact of CCR2 deficiency on prion disease. These results
are in line with previously reported data indicating that
CCR2 deficiency does not modify prion incubation times or
survival (Tamguney et al., 2008). We observe a similar expan-
sion of the microglial pool (Iba11 or PU.11 cells) in
response to prion disease in mice with a WT or CCR22/2
background. We did however observe an impact of CCR2
deficiency on the expansion of the perivascular macrophage
population driven by prion disease (Galea et al., 2005), which
is somewhat different compared to the results reported for
the APP/PS1 model of AD (Mildner et al., 2011), even
though the innate immune response in APP transgenics and
experimental models of prion disease share many similarities.
Different detection methods could be one reason for this dif-
ference and an in-depth analysis of the expression of specific
markers of perivascular macrophages, like CD163 or mannose
receptor (CD206; Galea et al., 2005, 2008; Hawkes and
McLaurin, 2009) will help to understand the dynamics of
this population in APP models. However, the behavioral
results obtained in this work indicate a negligible role of the
perivascular macrophage population during the progression of
prion disease. This is indicated by the fact that abolishing the
expansion of the perivascular macrophage population in
response to prion disease in CCR2 deficient mice had no
impact over the progression of the pathology.
The chemokine receptor CCR2 can bind all the mono-
cyte chemoattractant proteins, although it is the only estab-
lished high-affinity receptor for CCL2 (Charo et al., 1994;
Huang et al., 2005). Both CCL2 and CCR2 are upregulated
in prion disease, as reported in the present work and previ-
ously (Felton et al., 2005), indicating a potential role for of
this receptor-ligand interaction. CCL22/2 mice show an
amelioration of the behavioral deficits and a mild increase of
survival when infected with the ME7 prion strain, without
affecting the microglial population (Felton et al., 2005).
These effects were not replicated by genetic deletion of
CCR2. Instead we observed a small reduction of the expres-
sion of the mitogenic pathways controlling microglial prolifer-
ation (CSF1R). The activity of the CCL2-CCR2 pathway has
been previously shown to stimulate microglial proliferation
(Hinojosa et al., 2011), although this reported link of CCR2
with microglial proliferation was not observed in CSF1-
treated cells isolated from CCR22/2 mice (Mildner et al.,
2007). Although we observed a reduction in microglial prolif-
eration it did not impact the endpoint expansion of the cell
population, indicating that other balancing forces could be
modulated by CCR2 deficiency, as for example apoptosis of
microglial cells (Gomez-Nicola et al., 2013). Our results indi-
cating a minimal impact of CCR2 deletion on the inflamma-
tory state of microglial cells are in accord with previously
reported evidence with microglia isolated from CCR22/2
mice, which show no differences from WT microglia with
regard to expression of IL6, TNFa, or MCH class II after
stimulation with LPS or Pam3CSK4 (Mildner et al., 2007). It
is also interesting to be noted that CCR2 was not detected
on microglial cells throughout development (Mizutani et al.,
2012). Therefore, the effects of the activation of the CCL2/
CCR2 system on the control of cell proliferation would need
to be further explored, to better understand the discrepancies
present in the literature.
CCL2 is expressed by astrocytes through the TNF-a/
JNK pathway (Gao et al., 2009), activated microglia in senile
Ab plaques, and reported to be expressed by some neurons
(Hickman and El Khoury, 2013). Although the expression of
CCR2 in the brain has been reported in neurons in the spinal
cord (Gao et al., 2009), in certain regions of the brain (Bose
and Cho, 2013), including the neurogenic niches (Tran et al.,
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2007), its expression in the brain has been defined by other
authors to be specific to infiltrating precursors, and is not
present on any other cell from the microglial or neuroepithe-
lial lineage (Mizutani et al., 2012; Saederup et al., 2010). We
here report CCR2 expression in perivascular macrophages,
and we hypothesize that a deficient or aberrant signal derived
from the perivascular compartment might be responsible for
the observed decrease in the proliferative activity of microglia
in CCR22/2 ME7 mice. The impact of CCR2, independent
of its effect on the microglia, has been previously described in
the brain. It has been reported that CCL2, in a CCR2-
dependent manner, can be neuroprotective against HIV-1
transactivator protein (Tat) toxicity in rat primary midbrain
neurons and after intrastriatal injection of Tat (Yao et al.,
2009). Similarly, CCR2 deficiency significantly reduces the
generation of neuropathic pain (Gao et al., 2009). In the
MPTP model of murine Parkinson’s Disease (PD), CCL2 is
upregulated in astrocytes and neurons, but the absence of
CCL2 and CCR2 does not protect against loss of dopaminer-
gic neurons in the striatum (Kalkonde et al., 2007). More
recently, CCR2 deficiency was shown to prevent
hippocampus-dependent spatial learning and memory impair-
ments induced by cranial irradiation, highlighting the poten-
tial neuron-specific functions of this receptor (Belarbi et al.,
2013; Raber et al., 2013). These contrasting views might be
explained by alternative ligands, besides CCL2: binding and
signaling through CCR2 can be achieved by CCL2, CCL7,
CCL8, CCL12, and CCL13 (Bose and Cho, 2013). For
example, CCL8 was reported to elicit the CCR2-mediated
neuroprotective effects after irradiation (Belarbi et al., 2013).
Together with the findings reported here, the literature sup-
ports a re-evaluation of the expression levels and activity of
the system of CCR2 and its ligands in the brain, to better
understand its functions in different brain cells.
To summarize, our results support the evidence that the
expansion and activation of the microglial population in
chronic neurodegeneration is independent of the recruitment
of circulating monocytes. We highlight the relevance of
CCR2 for the control of the dynamics of the perivascular
macrophage population. Our results clearly define the exis-
tence of three compartments, the blood, the perivascular com-
partment and the brain parenchyma that regulate immune-to-
brain communication. Careful evaluation of the dynamics
between these compartments will be key to understanding the
influence of the innate immune response on the progression
of chronic neurodegeneration.
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